Liquid Biopsy Enabling Precision Oncology Clinical Trials

• Defining ctDNA guided clinical trial designs and assay performance requirements for each
• Showcasing ctDNA as a key secondary endpoint of th e TRIDENT-1 clinical trial, a case study discussion
• Partnering on the development of a WGS MRD distributed kit

Speakers:

Jonathan Beer

Senior Director, Precision Medicine

Bristol Myers Squibb